HIV Infections
Conditions
Keywords
Didanosine, Drug Therapy, Combination, Stavudine, Hydroxyurea, Anti-HIV Agents
Brief summary
To determine the virologic benefits associated with the addition of hydroxyurea (HU) to combination drug therapy with didanosine (ddI), stavudine (d4T), and efavirenz (DMP) in HIV-infected patients. To assess the safety and tolerance of this regimen, with or without HU.
Detailed description
HU or placebo is added 30-60 days after the initiation of DMP, ddI, and d4T combination therapy. Patients are stratified according to antiretroviral experience (naive or experienced). Patients are followed for 48 weeks to determine safety, efficacy, and effect of treatment on viral, immunologic,and biochemical parameters.
Interventions
DRUGHydroxyurea
DRUGEfavirenz
DRUGStavudine
DRUGDidanosine
Sponsors
Northwestern University
Study design
Primary purpose
TREATMENT
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Patients must have: * HIV infection, as documented by a licensed ELISA that is confirmed either by Western blot, positive HIV culture, positive HIV antigen, positive plasma HIV RNA, or a second antibody test positive by a method other than ELISA. * CD4 cell count of at least 100 cells/mm3 within 30 days of study entry. * Over 500 HIV-1 RNA copies/ml as measured by the Roche Amplicor or Ultra Sensitive Assay within 30 days of study entry. * Treatment-experienced patients must have documented HIV RNA values of less than or equal to 100,000 copies/ml within 30 days of study entry. Prior Treatment: Excluded: Acute therapy for an infection or other medical illness. Acute therapy must have been completed 14 days prior to the time of study entry.
Exclusion criteria
Co-existing Condition: Patients with the following symptoms or conditions are excluded: Malignancy requiring systemic therapy. Patients with the following prior conditions are excluded: * History of acute or chronic pancreatitis. * History of generalized peripheral neuropathy. * Inability to tolerate ddI at 200-400 mg/day or d4T at 60-80 mg/day. For purposes of this study, intolerance will be defined as the same recurrent toxicities requiring dose interruptions and dose reductions or permanent discontinuation of the drugs (other than Grade 3 or 4 anemia). Prior Medication: Excluded: Antiretroviral therapy. If antiretroviral-experienced, no prior NNRTI's or HU and no more than 12 weeks experience with ddI and/or d4T. Protease inhibitor experience is allowed. Experienced patients must be on a stable antiretroviral therapy 30 days prior to study screening and continue this regimen until study entry. Risk Behavior: Excluded: Current ethanol abuse by personal history or a report from a primary physician.
Countries
United States
Outcome results
None listed